Aclaris Therapeutics Inc. plans to sell up to $75 million of its common stock in an underwritten public offering.
The company will grant underwriters an option to buy up to an additional $11.3 million of common stock.
Jefferies LLC and Leerink Partners LLC are acting as joint book-running managers for the offering. William Blair & Co. LLC, Guggenheim Securities LLC, and JMP Securities LLC are acting as co-managers for the offering.